Opus Genetics (NASDAQ:IRD) Stock Breaks Below 200-Day Moving Average – Here’s What Happened

Opus Genetics, Inc. (NASDAQ:IRD – Get Free Report) passed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $4.23 and traded as low as $3.96. Opus Genetics shares last traded at $4.06, with a volume of 1,387,998 shares traded.

Analysts Set New Price Targets

A number of research firms recently commented on IRD. Wall Street Zen downgraded Opus Genetics from a “hold” rating to a “sell” rating in a research note on Saturday, November 7th. Citizens Jmp reiterated a “market outperform” rating and set a $17.00 price objective on shares of Opus Genetics in a research note on Friday, October 16th. Zacks Research raised shares of Opus Genetics from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. BTIG Research restated a “buy” rating and issued a $12.00 target price on shares of Opus Genetics in a research report on Wednesday, September 9th. Finally, Wedbush upped their price target on shares of Opus Genetics from $10.00 to $13.00 and gave the stock an “outperform” rating in a report on Thursday, September 10th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $13.29.

Check Out Our Latest Research Report on IRD

Opus Genetics Stock Performance

The company has a 50 day moving average price of $4.50 and a 200-day moving average price of $4.23. The company has a current ratio of 9.65, a quick ratio of 12.19 and a debt-to-equity ratio of 0.90. The company has a market cap of $392.40 million, a P/E ratio of -2.60 and a beta of 0.80.

Opus Genetics (NASDAQ:IRD – Get Free Report) last posted its quarterly earnings results on Tuesday, November 10th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.31). The firm had revenue of $1.14 million during the quarter, compared to the consensus estimate of $1.55 million. On average, equities analysts expect that Opus Genetics, Inc. will post -1.04 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Opus Genetics news, President Benjamin Yerxa sold 33,189 shares of the business’s stock in a transaction dated Friday, October 23rd. The stock was sold at an average price of $3.54, for a total transaction of $117,489.06. Following the completion of the transaction, the president owned 670,917 shares of the company’s stock, valued at approximately $2,375,046.18. The trade was a 4.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Fighting Blindness Foundation sold 556,000 shares of the stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $4.96, for a total transaction of $2,757,760.00. Following the completion of the transaction, the director directly owned 3,236,171 shares of the company’s stock, valued at $16,051,408.16. This trade represents a 14.66% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 673,805 shares of company stock worth $3,213,582 in the last ninety days. Insiders own 11.70% of the company’s stock.

Hedge Funds Weigh In On Opus Genetics

A number of institutional investors have recently added to or reduced their stakes in IRD. BlackRock Inc. bought a new position in Opus Genetics in the 2nd quarter valued at approximately $12,809,000. Nantahala Capital Management LLC bought a new stake in shares of Opus Genetics during the second quarter worth $12,582,185. Trails Edge Capital Partners LP bought a new stake in shares of Opus Genetics during the second quarter worth $11,276,434. ADAR1 Capital Management LLC grew its stake in shares of Opus Genetics by 4,522.5% during the first quarter. ADAR1 Capital Management LLC now owns 1,849,004 shares of the company’s stock worth $8,413,000 after buying an additional 1,809,004 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new position in shares of Opus Genetics during the second quarter worth $1,360,000. 14.97% of the stock is currently owned by institutional investors and hedge funds.

About Opus Genetics

(Get Free Report)

Opus Genetics, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases, rare conditions that can cause progressive vision loss. Its programs target specific genetic causes of these disorders, including mutations associated with Leber congenital amaurosis and retinitis pigmentosa. The company’s therapies are investigational and are designed to address the underlying genetic defects rather than only manage symptoms. Opus Genetics was formed through the combination of Opus Genetics and Ocuphire Pharma; the combined company took the Opus Genetics name and began trading on Nasdaq under the symbol IRD in 2024.

Further Reading

Receive News & Ratings for Opus Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opus Genetics and related companies with MarketBeat.com's FREE daily email newsletter.